Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline

Aysegul Gunduz, Hokuto Morita, P. Justin Rossi, William L. Allen, Ron L. Alterman, Helen Bronte-Stewart, Christopher R. Butson, David Charles, Sjaak Deckers, Coralie De Hemptinne, Mahlon Delong, Darin Dougherty, Jens Ellrich, Kelly D. Foote, James Giordano, Wayne Goodman, Benjamin D. Greenberg, David Greene, Robert Gross, Jack W. JudyEdward Karst, Alexander Kent, Brian Kopell, Anthony Lang, Andres Lozano, Codrin Lungu, Kelly E. Lyons, Andre MacHado, Hubert Martens, Cameron McIntyre, Hoon Ki Min, Joseph Neimat, Jill Ostrem, Sat Pannu, Francisco Ponce, Nader Pouratian, Donnie Reymers, Lauren Schrock, Sameer Sheth, Ludy Shih, Scott Stanslaski, G. Karl Steinke, Paul Stypulkowski, Alexander I. Troster, Leo Verhagen, Harrison Walker, Michael S. Okun

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

The proceedings of the 2nd Annual Deep Brain Stimulation Think Tank summarize the most contemporary clinical, electrophysiological, and computational work on DBS for the treatment of neurological and neuropsychiatric disease and represent the insights of a unique multidisciplinary ensemble of expert neurologists, neurosurgeons, neuropsychologists, psychiatrists, scientists, engineers and members of industry. Presentations and discussions covered a broad range of topics, including advocacy for DBS, improving clinical outcomes, innovations in computational models of DBS, understanding of the neurophysiology of Parkinson's disease (PD) and Tourette syndrome (TS) and evolving sensor and device technologies.

Original languageEnglish (US)
Pages (from-to)475-485
Number of pages11
JournalInternational Journal of Neuroscience
Volume125
Issue number7
DOIs
StatePublished - Jul 3 2015

Bibliographical note

Funding Information:
AG: Grant support from Medtronic, Inc.; HK: None; PJR: None; WLA: None; RLA: Consultant for Medtronic, Inc.; HB-S: None; CRB: Consultant for St Jude Medical, Boston Scientific; IP related to DBS; DC: Vanderbilt receives income from grants or contracts from Allergan, Ipsen, Merz and Medtronic for research led by DC; DC receives income from Allergan, Ipsen, Medtronic and, the Alliance for Patient Access for education or consulting services; SD: Employee and shareholder of Sapiens Steering Brain Stimulation GmbH (Medtronic Eindhoven Design Center); CDH: None; MDL: None; DD: Grant support from Medtronic, Cyberonics, Eli Lilly, Roche, Honoraria from Medtronic, Insys, Johnson & Johnson; JE: Chief Medical Officer at Sapiens Steering Brain Stimulation GmbH; KDF: Grant support from Medtronic, St. Jude, Boston Scientific, Neuropace; Consultant for Medtronic, Neuropace; JG: None; WG: None; BDG: None; DG: Employee of Neuropace; RG: None; JJ: None; EK: Employee of St. Jude Medical; AK: Employee of St. Jude Medical; BK: Consultant for Medtronic, St Jude Neuromodulation, MRI Interventions; ALang: Consultant for Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Lilly, Medtronic, Merck, Novartis, NeuroPhage Pharmaceuticals, Teva, UCB; Honoraria from Medtronic, Teva, UCB, AbbVie; Grant support from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation; Publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press; ALozano: Consultant for Medtronic, St Jude and Boston Scientific, Co-Founder of Functional Neuromodulation; CL: None; KL: Consultant for Medtronic, St. Jude Medical; AM: IP in Enspire, ATI, Cardionomics, Grant support from Medtronic, Inc., Consultant for Functional Neuro-modulation, Spinal Modulation; HM: Employee and shareholder of Sapiens Steering Brain Stimulation GmbH (Medtronic Eindhoven Design Center); CM: IP in Boston Scientific Neuromodulation; Consultant for Boston Scientific Neuromodulation; Shareholder in Autonomic Technologies, Inc., Cardionomics, Inc., Neuros Medical, Inc., Surgical Information Sciences, Inc.; BM: None; HKM: None; JN: Grant support from Medtronic, Inc.; Consultant for Medtronic, Inc., Mon-teris Inc.; JO: Grant support from Boston Scientific, MRI Interventions, St Jude Medical, Medtronic; SP: None; FP: Consultant for Medtronic, Inc; NP: None; DR: Employee of Neuromodulation, Inc; LSchrock: Site PI for the Boston Scientific INTREPID DBS trial; SSheth: None; LShih: None; SStanslanski: Employee of Medtronic, Inc.; GKS: Employee of Boston Scientific Neuromodulation; PS: Employee of Medtronic, Inc.; AT: Consultant for St Jude Medical, Boston Scientific, Theravance, Teva; Grant support from Glaxo Smith Kone, Speaker for Medtronic; Royalties from Oxford University Press; LV: None; HW: None; MSO: Consultant for National Parkinson Foundation; Grant support from NIH, NPF, Michael J. Fox Foundation, Parkinson Alliance, Smallwood Foundation, Bachmann-Strauss Foundation, Tourette Syndrome Association, UF Foundation.

Publisher Copyright:
© 2015 The Authors.

Keywords

  • Deep brain stimulation
  • Electrophysiology
  • Movement disorders
  • Neuroethics
  • neurotechnology

Fingerprint

Dive into the research topics of 'Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline'. Together they form a unique fingerprint.

Cite this